Right. Healthcare. Multi-trillion dollar industry, they say. Makes you feel…secure? No, not really. It just means there’s a lot of money sloshing around, and a lot of people hoping you won’t look too closely at where it’s all going. Five-point-three trillion dollars spent in 2024. Honestly, it’s terrifying. But also… potentially profitable. If you’re willing to play the game. Which, let’s be honest, most of us are. Regulatory pressures, political dramas… it’s all a bit of a circus, isn’t it? But circuses can be lucrative, if you pick the right performers. I’ve been staring at these charts, trying to convince myself I’m making sensible decisions. It’s a struggle, believe me.
Generally, you want the big players. The ones who’ve seen it all before and can probably navigate the chaos without completely collapsing. It’s not about finding the good companies, it’s about finding the ones that are most likely to survive the inevitable mess. Three of them, apparently. Here we go. Don’t blame me if this all goes south.
1. AbbVie
AbbVie. A pharmaceutical giant. Sounds… imposing. They do a bit of everything – immunology, neuroscience, oncology. It’s a broad net, which I suppose is the point. They’ve been around the block a few times, rebuilt their pipeline when things went stale. That’s smart. Drug patents expire, everyone knows that. It’s the pharmaceutical equivalent of a mid-life crisis – you need to reinvent yourself or fade into obscurity. They’re offering a 3% dividend yield. It’s… comforting. Like a small reward for participating in this whole, slightly unsettling system. A “Dividend King,” they call it. 50 years of increasing dividends. Impressive, if you ignore the fact that it’s still, fundamentally, a business built on human suffering. Analysts think they’ll grow earnings by 17% annually. Optimistic, aren’t they? I’ll believe it when I see it.
2. Eli Lilly
Eli Lilly. Now they’re onto something with this obesity drug market. $144 billion by the end of the decade, apparently. It’s… a lot of money. And a lot of pressure on people to conform to unrealistic beauty standards, but let’s not dwell on that. Their tirzepatide drug – Mounjaro, Zepbound – is taking market share from Novo Nordisk. Good for them. Competition is healthy, even if it’s driven by vanity. They’ve got a robust pipeline, too. Orforglipron coming up. Another drug. Another potential profit margin. And this Retatrutide thing… a triple agonist. Sounds terrifyingly complicated. But if the clinical trials are anything to go by, it could be a blockbuster. Wall Street thinks they’ll grow earnings by 25% annually. See, everyone’s an optimist. Except me, apparently. I’m just bracing for the inevitable disappointment.
3. Bristol Myers Squibb
Bristol Myers Squibb. Okay, this one’s a bit trickier. Patent expirations looming. Eliquis, Opdivo… facing generic competition. It’s the circle of life, I guess. Drugs lose exclusivity, profits decline, investors panic. But they had a strong fourth quarter. And they’ve got a pipeline, a “laundry list” of upcoming milestones, as they put it. Sounds exhausting. If they can replenish their business with new drugs, maybe, just maybe, they’ll generate decent returns. They’re offering a 4% dividend yield. And they trade at just 10 times forward earnings. Sounds… cheap. Almost too cheap. Analysts see 15% annual earnings growth. See a pattern here? Everyone’s projecting growth. I’m starting to suspect they’re all in on some elaborate conspiracy to make me feel better about my questionable investment decisions. There’s a lot of upside potential, they say. As long as they can bring their pipeline drugs to market. The usual caveats apply. Don’t say I didn’t warn you.
Read More
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Gold Rate Forecast
- Wuchang Fallen Feathers Save File Location on PC
- Brown Dust 2 Mirror Wars (PvP) Tier List – July 2025
- HSR 3.7 breaks Hidden Passages, so here’s a workaround
- 17 Black Actresses Who Forced Studios to Rewrite “Sassy Best Friend” Lines
- Crypto Chaos: Is Your Portfolio Doomed? 😱
- HSR Fate/stay night — best team comps and bond synergies
- The 10 Most Beautiful Women in the World for 2026, According to the Golden Ratio
- Elden Ring’s Fire Giant Has Been Beaten At Level 1 With Only Bare Fists
2026-02-19 20:23